Precision Neuroscience has closed an oversubscribed $250M Series D, co-led by
@PershingSquare Capital Management, The Ackman Oxman Institute, and a leading life sciences investment fund.
Total raised: ~$430M.
But the financing is only part of the story. Precision now has completed 100+ procedures across 18 major medical institutions. Building BCI requires more than an interface. It requires clinical infrastructure.
Since our last financing
@PrecisionNeuro_ has also:
- Received
@FDA clearance for Layer 7™
- Expanded peer-review clinical research
- Partnered with
@Medtronic
- Expanded U.S. MEMS manufacturing
The next phase of BCI will be defined not only by what the technology can do in a laboratory. It will be defined by whether companies can build the clinical, regulatory, and manufacturing infrastructure required to bring it to patients.
This funding will support:
- Expanded clinical work
- Additional FDA review
- Commercialization infrastructure
Read the full news release here:
globenewswire.com/news-relea…
@BillAckman @PershingSquare @BCapitalGroup,
@ARKInvest,
@MubadalaCapital,
@MiraeAsset,
@Hitachi Ventures.
Precision’s brain-computer interface is an investigational device and is not available for sale in the United States.